Intrasense : announces the appointment of Jérôme Thiebaud as Chief Business Officer

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.

Strong expertise in the medical imaging industry

Jérôme Thiebaud took up his position as Chief Business Officer at Intrasense on April 2, 2024. He will head up the Group's sales, marketing and services departments. He will play a key role in the Group's revenue growth, visibility and international development strategy.

With solid expertise in the healthcare sector, particularly in medical imaging, Jérôme has worked for several major companies including Philips Healthcare, GE Healthcare and Masimo. He has been responsible for the development of innovative new businesses, both in France and internationally, as well as for the digital transformation and service approach of various structures. With a master's degree in physical sciences from the Université de Savoie, Jérôme brings to Intrasense a combination of skills and experience to support its growth and expansion on the global market.

• We have real ambitions for growth in France and internationally, thanks to the excellent reputation of our products, and our ability to develop innovative solutions enhanced by artificial intelligence that will meet the challenges of healthcare professionals and institutions » comments Jérôme Thiebaud, Chief Business Officer of Intrasense.
• With major innovations coming to market in 2024, the creation of the CBO role is a key step. Jérôme's strong experience in medical imaging will help us continue our transformation and reach a new milestone in terms of commercial growth » adds Nicolas Reymond, CEO of Intrasense.

An ambition for strong commercial growth

The Group continues to deploy its growth strategy, based on innovations and its key markets. The new Myrian® version 2.12, recently launched after certification under new European regulations1, incorporates major innovations such as artificial intelligence algorithms for the prostate and lung. Intrasense is also preparing the

1 European Union Medical Devices Regulation 2017/745

Press release

1/2

launch of its new Liflow® platform, planned for the second half of 2024. Liflow®, enriched with several multi-organ AIs including liver lesion detection, offers a real paradigm shift in oncology monitoring software solutions.

These solutions offer major innovations at the highest world level, with AIs developed by the Guerbet Group, winner of the international PI-CAI Challenge for prostate cancer detection.

Intrasense is pursuing its development and diversification strategy in stable and growing markets, through direct sales or via commercial partners, and with the support of the Guerbet Group for co-promotion in certain countries. The Group is thus renewing its growth ambitions and strengthening its sales organization to position itself in its key markets and bring its innovations to them.

About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new platform

Intrasense Salomé Sylvestre Communications officer Phone: [phone]

dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

NewCap Thomas Grojean Financial Communication and investor relations Phone: [phone]

Press release

2/2